The global Kaposi’s Sarcoma market is expanding due to the HIV/AIDS prevalence, improved oncology infrastructure, and advancements in targeted and immunotherapeutic drugs. Kaposi’s Sarcoma, a tumor ...

Living with HIV comes with unique health challenges, but advances in treatment have transformed it into a manageable chronic ...

Who knows why different people have different symptoms with the common cold? Well, a new study used laboratory-grown noses ...

TB remains the leading cause of death among people living with HIV. Uganda is a high TB-burden country, and HIV accelerates ...

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

Opinion: Artist Carl George remembers his late friend Ross Laycock, whose life and love story with Felix Gonzalez-Torres left ...

Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...

Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...

Sanofi's amlitelimab confirms its potential in atopic dermatitis: Paris Saturday, January 24, 2026, 10:00 Hrs [IST] Following the positive COAST 1 (clinical study identifier: NCT0 ...

Kentuckians who have finished treatment for organ cancers and melanoma, among others, no longer need to wait more than a year ...